<DOC>
	<DOCNO>NCT01015911</DOCNO>
	<brief_summary>This phase 1 , open-label , dose-escalation clinical trial evaluate safety SGN-75 patient CD70-positive relapsed refractory non-Hodgkin lymphoma metastatic renal cell carcinoma .</brief_summary>
	<brief_title>A Phase 1 Dose-escalation Trial SGN-75 CD70-positive Non-Hodgkin Lymphoma Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pathologicallyconfirmed diagnosis NHL RCC Relapsed , refractory , progressive disease follow least 1 prior systemic therapy Confirmed CD70 expression Measurable disease , define least 1 lesion &gt; 1.5 cm great transverse diameter patient NHL , least 1 nonresectable tumor lesion &gt; equal 10 mm diameter patient RCC Previously receive allogeneic transplant History another primary malignancy remission least 3 year Prior antiCD70directed therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD70</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Carcinoma , Renal Cell</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>monomethylauristatin F</keyword>
</DOC>